| Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
| New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
| None | ||||||
| Postponed | ||||||
| None | ||||||
| Withdrawn | ||||||
| Good Technology (GDTC) | J.P. Morgan/ BofA Merrill Lynch/ Barclays | $100.00 | n.a. | |||
| New Terms | ||||||
| Adesto Technologies (IOTS) | Needham & Company/ Oppenheimer & Co. | 5.00 | $5.00 | $5.00 | $25.00 | 1-Star |
| ETRE Residential, LLC (EPNT) | Joseph Gunnar & Co. | 3.28 | $10.00 | $10.00 | $32.75 | n.a. |
| GenSight Biologics S.A. (GNST) | Leerink Partners/ Evercore ISI/ Canaccord Genuity | 4.65 | $13.00 | $15.00 | $65.10 | 1-Star |
| Voyager Therapeutics (VYGR) | Cowen and Company/ Piper Jaffray | 4.69 | $15.00 | $17.00 | $75.00 | n.a. |
| Xtera Communications (XCOM) | Needham & Company/ Cowen and Company/ BMO Capital Markets | 5.50 | $9.00 | $11.00 | $55.00 | 1-Star |
| n.a. (not available) | ||||||
| IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
| Week of Oct. 26, 2015 | Manager(s) | Offered | Raised | Price | 10/30/15 | Change |
| Adesto Technologies (IOTS) | Needham & Company/ Oppenheimer & Co. | 5.00 | $25.00 | $5.00 | $5.95 | 19.00% |
| MyoKardia (MYOK) | Credit Suisse/ Cowen and Company | 5.44 | $54.38 | $10.00 | $10.21 | 2.10% |
